Generic competition · all medicines · read 12 November 2026
Is there a generic of Betamethasone Dipropionate; Calcipotriene, and who makes it?
Betamethasone Dipropionate; Calcipotriene appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 7 and 12 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Betamethasone Dipropionate; Calcipotriene appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them.
- 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 7 and 12 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Suspension, Topical
One to three generic makers listed
Brand listed as marketed: Taclonex. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 11 May 2020.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Cosette Pharmaceuticals Nc Laboratories Llc | 11 May 2020 | 1 |
| Sun Pharma Canada Inc | 2 September 2020 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Ointment, Topical
One to three generic makers listed
Brand listed as marketed: Taclonex. 1 generic maker with 1 generic product listed as marketed; the first generic approval is dated 14 January 2013.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Padagis Israel Pharmaceuticals Ltd | 12 December 2014 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Aerosol, Foam, Topical
Brand listed, no generic listed as marketed
Brand listed as marketed: Enstilar. No generic is listed as marketed (1 generic product listed as discontinued).
Patents and exclusivities still listed
- 10 June 2031Patent 9119781 drug product
- 10 June 2031Patent 10688108
- 10 June 2031Patent 10660908 drug product
- 10 June 2031Patent 9566286 drug product
- 10 June 2031Patent 10130640 drug product
- 10 June 2031Patent 10617698 drug product
- 10 June 2031Patent 10682364 drug product
- 10 June 2031Patent 10716799 drug product
2 more patents are listed.
Cream, Topical
Brand listed, no generic listed as marketed
Brand listed as marketed: Wynzora. No generic is listed as marketed.
Patents and exclusivities still listed
- 27 September 2027Patent 10265265 drug product
- 18 March 2039Patent 12440499 drug product
- 18 March 2039Patent 11696919 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.